CD19 and B-cell chronic lymphocytic leukemia: Safety and efficacy of allo-HSCT in adults after CD19-targeted CAR-T cell therapy was also investigated in some other B-cell malignancies such as B-cell chronic lymphocytic leukemia (B-CLL) and non-Hodgkin lymphoma (NHL) and revealed the promising results [143].